2016 Fiscal Year Final Research Report
A proposal of treatment of atopic dermatitis targeted at the skin microflora and Langerhans cells
| Project/Area Number |
26460238
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Meiji Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
HINO Yumi
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | アトピー性皮膚炎 / 黄色ブドウ球菌 / ランゲルハンス細胞 / IgE / Th1細胞分化 / Th2細胞分化 / ジョサマイシン / アレルギー炎症 |
|---|
| Outline of Final Research Achievements |
The present study demonstrated that josamycin, a macrolide antibiotic, inhibited the development of Th1 and Th2 cells mediated by Langerhans cells and topical treatment with josamycin significantly suppressed the increase in the skin severity score in NC/Nga mice. Furthermore, Staphylococcus aureus strains isolated from skin lesions of patients with atopic dermatitis were highly susceptible to josamycin. Therefore, topical application of josamycin to atopic dermatitis lesions colonized by S. aureus would be beneficial for control of dermatitis and preferable to steroids.
|
| Free Research Field |
感染免疫学
|
